Deiana S, Harrington CR, Wischik CM, Riedel G. (2009) Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology 202:53-65.
Luna-Munoz J, Peralta-Ramirez J, Chavez-Macias L, et al. (2008) Thiazin red as a neuropathological tool for the rapid diagnosis of Alzheimer's disease in tissue imprints. Acta Neuropathologica 116:507-515.
Wischik C, Staff R. (2009) Challenges in the conduct of disease-modifying trials in Alzheimer's disease: practical experience from a phase 2 trial of TAU-aggregation inhibitor therapy. J Nutr Health Aging 13:367-369.
Wischik CM, Wischik DJ, Storey JMD, Harrington C. (2010) Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies. In Emerging drugs and targets for Alzheimer's disease. Volume 1: ß-Amyloid, Tau Protein and Glucose Metabolism, ed. A. Martinez. pp. 210-232. RSC Drug Discovery Series Cambridge: Royal Society of Chemistry.